

NCCN Acute Myeloid Leukemia V.2.2013 – Web Conference – September 11, 2012

Guideline Page and Request	Panel Discussion	References	Vote		
			YES	NO	ABSTAIN
Internal request; AML-7: Consider adding cytarabine + daunorubicin + cladribine as an induction regimen.	Based on the data in the noted reference, the panel consensus was to add the regimen of cytarabine + daunorubicin + cladribine as a category 1 option for induction therapy in patients younger than 60 years.	Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. <i>J Clin Oncol</i> 2012;30:2441-2448.	14	0	0
Internal request; AML-8 and AML-9: Consider adding salvage therapy options for patients with induction failure.	Based on the data in the noted references, the panel consensus was to add salvage therapy options for patients with induction failure (including patients with significant residual blasts after induction).	<ul style="list-style-type: none"> • Martin MG, Welch JS, Augustin K, et al. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. <i>Clin Lymphoma Myeloma</i> 2009;9(4):298-301. • Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (FLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. <i>Eur J Haematol</i> 2008;80(2):115-126. • Montillo M, Mirto S, Petti MC, et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. <i>Am J Hematol</i> 1998;58:105–109. • Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. <i>Br J Haematol</i> 1997;99(4):939-944. • Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>J Clin Oncol</i> 1991;9(7):1210-1214. • Becker PS, Kantarjian HM, Appelbaum FR, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. <i>Br J Haematol</i> 2011;155:182-189. 	14	0	0